FDA Approves New Qelbree Nonstimulant Option For Adult ADHD

The U.S. Food and Drug Administration (FDA) approved the use of Qelbree (viloxazine extended-release capsules) as a nonstimulant treatment for adults diagnosed with attention deficit hyperactivity disorder (ADHD). Qelbree was developed by Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The FDA had previously approved Qelbree to treat ADHD in children age six and older.

Qelbree is a novel nonstimulant taken once-daily for full-day exposure. Efficacy and symptom improvement was observed early in treatment. It has a proven safety and tolerability profile, with . . .